

BOX PCT

"Express Mail" mailing label number EL 742889025 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED
OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER		
KILS117129		
U.S. APPLICATION NO. (if known see 37 C.F.R. 1.5)		
09/786992		
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/US99/07720	10 September 1999	10 September 1998
TITLE OF INVENTION		
METHOD FOR DETERMINING SUSCEPTIBILITY TO HEART DISEASE BY SCREENING POLYMORPHISMS IN THE VITAMIN D RECEPTOR GENE		
APPLICANT(S) FOR DO/EO/US		
Andreas Gerardus UITTERLINDEN, Petrus Thomas Maria VAN LEEUWEN and Huibert Adriaan Pieter POLS		

Applicants herewith submit to the United States Designated/Elected Office (DO/EO/US) the following items and other information by Express Mail:

- ☒ 1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
- ☐ 2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 37 U.S.C. 371.
- ☒ 3. This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).
- ☒ 4. The U.S. has been elected by the expiration of 19 months from the priority date (PCT Article 31).
- ☒ 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
- ☒ a. is attached hereto (required only if not transmitted by the International Bureau).
- ☐ b. has been transmitted by the International Bureau.
- ☐ c. is not required, as the application was filed in the United States Receiving Office (RO/US).
- ☐ 6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).

- X 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
- _____ a. are attached hereto (required only if not communicated by the International Bureau).
- _____ b. have been transmitted by the International Bureau.
- _____ c. have not been made; however, the time limit for making such amendments has NOT expired.
- X d. have not been made and will not be made.
- _____ 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
- _____ 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
- _____ 10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

- _____ 11. An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.
- _____ 12. An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.
- _____ 13a. A FIRST preliminary amendment.
- _____ 13b. A SECOND or SUBSEQUENT preliminary amendment.
- _____ 14. A substitute specification.
- _____ 15. A change of power of attorney and/or address letter.
- X 16. Other items or information:
- X a. amended page 2 of the specification and amended claims filed under PCT Article 34; and
- X b. copy of the International Preliminary Examination Report.

09/786992

JC02 Rec'd PCT/PTO 1 2 MAR 2001

X 17. The following fees are submitted:.				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1,000 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..... \$860 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$710 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... \$690 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100 ENTER APPROPRIATE BASIC FEE AMOUNT =				\$860	
Surcharge of \$130 for furnishing the oath or declaration later than ____ 20 ____ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	20- 20 =	0	X \$18	\$	
Independent claims	3 - 3 =	0	X \$80	\$	
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)			+ \$270	\$	
TOTAL OF ABOVE CALCULATIONS =				\$	
____ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
SUBTOTAL =				\$860	
Processing fee of \$130 for furnishing the English translation later than ____ 20 ____ 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$0	
TOTAL NATIONAL FEE =				\$860	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property				\$	
TOTAL FEES ENCLOSED =				\$860	
				Amount to be: refunded	\$
				charged	\$

X 17a. A check in the amount of \$860.00 to cover the above fees is enclosed. Check No. 126041.

09/786992

JC02 Rec'd PCT/PTO 1 2 MAR 2001

X 17c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 03-1740. A duplicate copy of this sheet is enclosed.

SEND ALL CORRESPONDENCE TO:

Barry F. McGurl
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, WA 98101

Respectfully submitted,

CHRISTENSEN O'CONNOR
JOHNSON KINDNESS^{PLLC}



Barry F. McGurl
Registration No. 43,340
Direct Dial (206) 695-1775

EXPRESS MAIL CERTIFICATE

"Express Mail" mailing label number: EL 742889025 US
Date of Deposit March 9, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

YVETTE D. LOVETT
(Typed or printed name of person mailing paper or fee)

[Handwritten Signature]
(Signature of person mailing paper or fee)

BFM:jlj

09/786992 BOX PCT

Rec'd PCT/PTO 3 0 MAY 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: A.G. Uitterlinden et al. Attorney Docket No.: KILS117129
Application No.: 09/786,992
Filed: March 9, 2001
Title: METHOD FOR DETERMINING SUSCEPTIBILITY TO HEART DISEASE
BY SCREENING POLYMORPHISMS IN THE VITAMIN D RECEPTOR
GENE

PRELIMINARY AMENDMENT

Seattle, Washington 98101

May 24, 2001

TO THE COMMISSIONER FOR PATENTS:

Please enter the following Preliminary Amendment into the above-referenced patent application.

In the Specification:

On page 1, immediately after the title, please enter the following:

RELATED APPLICATIONS

The present application is the U.S. national phase of PCT/EP99/07720, filed September 10, 1999, which claims benefit of priority from British Patent Application No. GB9819764.3, filed on September 10, 1998, the benefit of priority of which applications is claimed under 35 U.S.C. § 119 and 120.

Amend page 8, lines 1-2 as follows:

1. 5'-CAACCAAGACTACAAGTACCGCGTCAGTGA-3' (SEQ ID NO:1) and/or
2. 5'GCAACTCCTCATGGCTGAGGTCTC-3' (SEQ ID NO:2)

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206 682.8100

In The Claims:

Amend Claims 4, 5, 7, 9, 11, 13-16, 18 and 19 as follows.

1. A method of determining susceptibility to heart disease in a subject, said method comprising analysing genetic material of a subject to determine which of the B/b, A/a or T/t alleles of the *BsmI*, *ApaI* or *TaqI* sites of the vitamin D receptor gene is/are present, wherein the b, a or T allele(s) are associated with risk of heart disease.
2. A method of determining susceptibility to heart disease according to claim 1, said method comprising analysing the genetic material of a subject to determine the haplotype of the *BsmI*, *ApaI* or *TaqI* alleles of the vitamin D receptor.
3. A method according to claim 2 wherein the haplotype may be determined by amplification of a relevant portion of the vitamin D receptor gene, followed by restriction enzyme digestion.
4. (Amended) A method of determining susceptibility to heart disease according to Claim 1, 2 or 3, said method comprising determining the copy number of the B/b, A/a or T/t alleles or haplotype of the vitamin D receptor.
5. (Amended) A method according to Claim 1 further comprising determining whether the allele(s) present is/are associated with risk of heart disease.
6. A method according to claim 5 comprising comparing the allele(s) present in the genetic material of the subject with those known to be associated allele(s) of vitamin D receptor genotypes having known ° of risk of heart disease.
7. (Amended) A method according to Claim 1 wherein said method further comprises determining aspects of calcium metabolism in a subject.
8. A method according to claim 7, wherein daily calcium intake of a subject is measured.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

9. (Amended) A method according to Claim 1, wherein said method is performed *in vitro*.
10. A method according to claim 9 wherein said method is performed on blood or tissue samples of a subject.
11. (Amended) A method according to Claim 1 wherein the subject is a mammal.
12. A method according to claim 11 wherein the subject is a human.
13. (Amended) A method according to Claim 11 or Claim 12 wherein the subject is male.
14. (Amended) A method according to Claim 1 for determining susceptibility of a subject to atrial or ventricular hypertrophy, aortic calcification, myocardial infarction, or hypertension.
15. (Amended) A method according to Claim 1 further comprising treating the subject to reduce the risk of heart disease.
16. (Amended) A method according to claim 15 wherein said treatment is selected from the group of treatments consisting of modifications to lifestyle, regular exercise, changes in diet and pharmaceutical preparations.
17. A method of predicting the response of a subject to treatment, said method comprising analysing genetic material of a subject to determine which of the B/b, A/a or T/t allele(s) of the vitamin D receptor gene is/are present, in order to determine the underlying cause of the heart disease.
18. (Amended) A method according to claim 17 wherein said subject is first diagnosed as being susceptible to heart disease in accordance with Claim 1.
19. (Amended) A method according to Claims 17 or 18 further comprising administering the appropriate treatment to the subject.

20. Use of a kit to determine susceptibility to heart disease in a subject, said kit comprising (i) one or more nucleic acid primer molecules for amplification of a portion of the vitamin D receptor gene, and (ii) means for determining which allele(s) of said gene is/are present.

21. A kit for determining susceptibility to heart disease in a subject, said kit comprising (i) one or more nucleic acid primer molecules for amplification of a portion of the vitamin D receptor gene; (ii) means for determining which allele(s) of said gene is/are present; and (iii) means for indicating correlation between said allele(s) and risk of heart disease.

22. A kit according to claim 21, said kit comprising DNA control samples, for comparison with DNA sequences of a subject.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

REMARKS

This preliminary amendment conforms the claim dependencies of the above-referenced patent application to U.S. practice. The Examiner is requested to enter the foregoing amendments prior to examining the application.

Enclosed is a certified copy of the following application for which a claim of priority under 35 U.S.C. § 119 has been made:

<u>Country</u>	<u>Serial No.</u>	<u>Filed</u>
Great Britain	GB9819764.3	10 September 1998

Respectfully submitted,

CHRISTENSEN O'CONNOR
JOHNSON KINDNESS^{PLLC}



Barry F. McGurl
Registration No. 43,340
Direct Dial No. 206.695.1775

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to the Commissioner for Patents, Washington, D.C. 20231, on the below date.

Date: 5/24/01



BFM:jlj

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

VERSION WITH MARKINGS TO SHOW CHANGES MADE MAY 24, 2001

In the Specification:

On page 1, immediately after the title, the specification has been amended as follows:

RELATED APPLICATIONS

The present application is the U.S. national phase of PCT/EP99/07720, filed September 10, 1999, which claims benefit of priority from British Patent Application No. GB9819764.3, filed on September 10, 1998, the benefit of priority of which applications is claimed under 35 U.S.C. § 119 and 120.

On page 8, lines 1-2 have been amended as follows:

1. 5'-CAACCAAGACTACAAGTACCGCGTCAGTGA-3' (SEQ ID NO:1) and/or
2. 5'GCAACTCCTCATGGCTGAGGTCTC-3' (SEQ ID NO:2)

In the Claims

4. (Amended) A method of determining susceptibility to heart disease according to [claims 1 to 3] Claim 1, 2 or 3, said method comprising determining the copy number of the B/b, A/a or T/t alleles or haplotype of the vitamin D receptor.

5. (Amended) A method according to [any one of the preceding claims] Claim 1 further comprising determining whether the allele(s) present is/are associated with risk of heart disease.

7. (Amended) A method according to [any one of the previous claims] Claim 1 wherein said method further comprises determining aspects of calcium metabolism in a subject.

9. (Amended) A method according to [any one of the preceding claims] Claim 1, wherein said method is performed *in vitro*.

11. (Amended) A method according to [any one of the preceding claims] Claim 1 wherein the subject is a mammal.
13. (Amended) A method according to claim[s] 11 or Claim 12 wherein the subject is male.
14. (Amended) A method according to [any one of the previous claims] Claim 1 for determining susceptibility of a subject to atrial or ventricular hypertrophy, aortic calcification, myocardial infarction, or hypertension.
15. (Amended) A method according to [any one of the preceding claims] Claim 1 further comprising treating the subject to reduce the risk of heart disease.
16. (Amended) A method according to claim 15 wherein [suitable] said treatment[s may include] is selected from the group of treatments consisting of modifications to lifestyle, regular exercise, changes in diet [or] and pharmaceutical preparations.
18. (Amended) A method according to claim 17 wherein said subject is first diagnosed as being susceptible to heart disease in accordance with [any one of] claim[s] 1 [to 16].
19. (Amended) A method according to claims 17 or 18 further comprising administering the appropriate treatment to the subject.

5/PR TS

09/786992

JC02 Rec'd PCT/PTO 1 2 MAR 2001

PCT/EP99/07720

WO 00/15840

1

METHOD FOR DETERMINING SUSCEPTIBILITY TO HEART DISEASE BY SCREENING POLYMORPHISMS IN THE VITAMIN D RECEPTOR GENE

5 The present invention relates to a prognostic method and prognostic means based on polymorphisms in the vitamin D receptor gene. In particular, the present invention relates to a method for determining susceptibility to heart disease by screening for polymorphisms in the vitamin D receptor gene.

10 Heart disease such as myocardial infarction is a complex phenotype caused by interaction of a number of genetic and environmental factors.¹ Advances in molecular genetics have led to the identification of a number of genetic risk factors for heart disease, such as gene variants involved in thrombosis^{2,3} and lipid metabolism⁴. However, another important risk factor for heart disease such as myocardial infarction is a deregulated calcium homeostasis which is required for maintenance of neuromuscular activity⁵. Disturbances of the calcium balance have
15 been implicated in hypertension, ventricular hypertrophy, aortic calcification and arrhythmias all of which are important risk factors associated with myocardial infarction.

20 Vitamin D is a potent regulator of bone and calcium homeostasis, as well as of cellular differentiation and replication in many tissues, and mediates its effects through the vitamin D receptor (VDR). Cloning of the vitamin D receptor has shown it to be a member of the ligand-activated superfamily, which are natural regulators of a number of physiological and developmental processes. The major physiological function of the active metabolite of vitamin D, i.e. 1,25(OH)₂D₃, is to
25 maintain serum calcium levels in the normal range. This is accomplished by stimulating the small intestine to increase its efficiency of absorbing calcium from the diet and to mobilize calcium stores from bone. The action of the hormone is mediated by the vitamin D receptor (VDR), a steroid transcription factor that

mediates hormone response by initiating gene transcription and mRNA translation⁶. Involvement of the vitamin D endocrine system in the etiology of heart disease was suggested by epidemiological studies which found serum levels of 25-hydroxyvitamin D₃ to be reduced in myocardial infarction patients compared with control individuals⁷. Furthermore, congestive heart failure associated with vitamin D deficiency has been described in a three and a half month old child⁸. The involvement of the vitamin D endocrine system in cardiac arrhythmias was suggested by case reports involving the observation of atrial flutter in a foetus with X-linked vitamin D resistant rickets⁹ and sick sinus syndrome that was cured by administration of vitamin D to a 77-year old caucasian woman¹⁰. Further studies in the rat have also demonstrated an important role of the vitamin D endocrine system in cardiovascular function, wherein vitamin D₃-deficiency can lead to large increases in the contractile function of the heart ¹⁷⁻²⁰.

The above studies establish a link between the vitamin D endocrine system and risk of heart disease in an individual. Further studies (Carling *et al*, JCE&M, 82 (6) 1772-1775 (1997); Carling *et al*, Nature Medicine, 1 (12) 1309-1310 (1995) and Carling *et al*, JCE&M 83 (7) 2255-2259 (1998) show an association between the *b*, *a* and *T* alleles of the vitamin D receptor gene and hyperparathyroidism. Hypertension is considered to be a feature of hyperparathyroidism (Boucher, B. J. of Nutr., 79 315-327 (1998). However, the genetic component of heart disease such as myocardial infarction or cardiac arrhythmia is poorly defined. As a result, methods of diagnosing risk of heart disease, or treating those suffering from heart disease, are restricted.

Thus, in a first aspect of the present invention, there is provided a method of determining susceptibility to heart disease in a subject, said method comprising analysing genetic material of a subject to determine which allele(s) of the vitamin D receptor is/are present.

The vitamin D receptor gene (12q12) comprises inherited polymorphisms between exon 7 and the 3' UTR of the VDR gene, as shown in Figure 1. These alleles are

denoted B/b, A/a and T/t for restriction enzyme sites *BsmI*, *ApaI* and *TaqI* respectively (or enzymatic or chemical procedures with similar specificities), where a lower case letter denotes the presence of a wild type restriction site which is capable of being cleaved, and a capital letter denotes the presence of a mutant restriction enzyme site which is not capable of being cleaved by the relevant restriction enzyme. For the purposes of the present invention, determination of which alleles are present in a particular gene may be referred to as determining the genotype of a subject for a particular gene. It is apparent from the above that each copy of the vitamin D receptor gene will comprise a specific combination of the three alleles, this combination being referred to as the haplotype of the gene. For example, the haplotype may be baT, indicating the presence of cleavable *BsmI* and *ApaI* sites, and a non-cleavable *TaqI* site. Direct haplotyping of the VDR gene has allowed five different haplotypes to be determined, of which three are common.¹⁶

The present invention is based on the discovery of a genetic component of heart disease. It has now been shown that presence of the b, a or T alleles, and in particular the baT haplotype of the vitamin D receptor is/are associated with increased risk of heart disease. Thus, the presence of such alleles of the vitamin D receptor gene may be used to determine susceptibility to heart disease.

Preferably, the method of the first aspect of the present invention comprises the additional step of determining whether the alleles present are associated with risk of heart disease. This may be performed by comparing the alleles present in the genetic material of the subject with genotypes of the vitamin D receptor having known degrees of risk of heart disease. For example, a visual aid detailing alleles and their relative risk of heart disease may be used to determine whether the genotype of the subject is associated with a high or low risk of heart disease.

5

10

15

20

25

b, a or T alleles is associated with increased risk of heart disease. Homozygosity for the a, b or T allele may further increase the susceptibility to heart disease in a subject.

5 In a preferred feature of the first aspect, there is provided a method of determining susceptibility to heart disease in a subject, said method comprising analysing the genetic material of a subject to determine the haplotype of the *BsmI*, *ApaI* and *TaqI* alleles at the vitamin D receptor. Preferably, said method comprises determining whether the haplotype of the subject is associated with risk of heart disease, wherein
10 the haplotype baT is associated with high risk of heart disease. A subject homozygous for said haplotype may be at a higher risk of heart disease than those heterozygous for the haplotype.

15 In a preferred feature of the first aspect, there is provided a method of determining susceptibility to heart disease, said method comprising the additional step of determining the copy number of the B/b, A/a or T/t alleles or haplotype of the vitamin D receptor, where an increase in copy number is associated with increased risk of heart disease.

20 The present invention may be performed using any suitable method known in the art. Preferably, a tissue or fluid sample is first removed from a subject. Examples of suitable samples include blood, mouth or cheek cells, and hair samples containing roots. Other suitable samples would be known to the person skilled in the art. The genetic material is then extracted from the sample for diagnosis, using any suitable
25 method. The genetic material may be DNA or RNA, although preferably DNA is used. For example, the DNA may be extracted using the technique described in Sambrook *et al* (Molecular Cloning- A Laboratory Manual, Cold Spring Harbor Laboratory Press). Determination of the genotype of a subject may then be carried

out using the extracted DNA, employing any one of the following techniques:

- Southern blot analysis following digestion with one or more appropriate restriction enzymes.
- 5 ▪ PCR amplification followed by digestion with one or more appropriate restriction enzymes and, optionally, separation of digestion products by gel electrophoresis.
- Sequencing of a relevant gene fragment by any suitable method.
- Visualization of heteroduplex patterns, for example on PAA or agarose gels, where different patterns may indicate the presence of one or more specific alleles.
- 10 ▪ Separation of DNA fragments using denaturing gradient gels, wherein the degree of separation will depend upon the presence or absence of one or more polymorphic restriction sites.
- Separation using SSCP analysis, the patterns of which will depend upon the presence or absence of one or more polymorphic restriction sites.
- 15 ▪ Use of allele specific oligonucleotides, hybridization patterns of which will be specific for various combinations of alleles.
- Methods such as OLA, Taqman or dot-blot for the detection of known mutations.
- Visualization of DNA sites using fluorescent labelled probes for alleles of interest.
- 20 ▪ RFLP analysis

Where it is desirable to use particular restriction enzymes in performing the present invention, the skilled person will understand that enzymatic or chemical procedures having similar specificities may also be used. For example, restriction enzymes having similar specificity (isoschizomers) to those described herein may be used, or chemical degradation procedures with DNA or RNA cutting specificity.

25

Other techniques suitable for determining the genotype of a subject may be used in the present invention.

Where the haplotype of a gene is to be determined, it is preferable to use a direct
5 haplotyping method, as described in Uitterlinden *et al*¹⁶. In such a method, the
relevant portion of the gene is amplified and then subjected to restriction enzyme
digestion, in order to determine the presence or absence of restriction enzyme sites.
Thus, for example, where the haplotype of the vitamin D receptor gene is to be
determined, the portion of the gene between exon 7 and the 3' UTR may be
10 amplified, and the amplified DNA digested with the *BsmI*, *ApaI* or *TaqI* restriction
enzymes. Gel analysis may then be used to determine which alleles are present.

Preferably, a fragment may be amplified using polymerase chain reaction (PCR)
techniques, to produce copies which, where the fragment is of the vitamin D
15 receptor, are at least 1000 base pairs in length, and most preferably at least 1800
base pairs in length. PCR techniques are well known in the art, and it is within the
ambit of the skilled person to identify primers for amplification of the appropriate
region of the above genes, namely the region from exon 7 to the 3' UTR of the
vitamin D receptor gene. PCR techniques are described in EP-A-0200362 and EP-
20 A-0201184.

In a preferred feature of the first aspect, there is provided a method of determining
susceptibility to heart disease in a subject, said method comprising amplifying a
fragment comprising a portion of the region from exon 7 to the 3' UTR of the
25 vitamin D receptor gene, and determining which allele(s) in the vitamin D receptor
is/are present. Primers suitable for amplification of said portion of the vitamin D
receptor gene would be readily available to a person skilled in the art. Examples of
such primers include:

20 In a third aspect of the present invention, there is provided a method of predicting the response of a subject to treatment, said method comprising analysing genetic material of a subject to determine which allele(s) of the vitamin D receptor gene is/are present. Preferably, the method includes first determining whether the subject is susceptible to heart disease. Where a subject has been determined as susceptible to heart disease, the method may further comprise administering the appropriate treatment. The present aspect of the invention is based on the observation that agents, such as calcium channel blockers, which are useful for treatment of a variety of cardiovascular diseases may also be associated with cardiovascular morbidity in some cases. The effect of an

25

agent may therefore depend on the underlying cause of the heart disease. For example, the presence of the b, a or T alleles of the vitamin D receptor may result in modification of calcium uptake, leading to impaired cardiovascular function. Thus, in such a case it would be preferable to avoid the use of calcium channel blocking agents.

5

In a fourth aspect of the present invention, there is provided use of a kit to determine which allele(s) of the vitamin D receptor gene is/are present, said kit comprising (i) one or more nucleic acid primer molecules for amplification of a portion of the vitamin D receptor gene, and (ii) means for determining which allele(s) is/are present in said gene.

10

Preferably, the primer molecules are suitable for amplification of at least a portion of the region between exon 7 and the 3'UTR of the vitamin D receptor gene. Examples of suitable primers are described above.

15

Means for determining which allele(s) is/are present in the vitamin D receptor gene, may include any reagents or molecules necessary for use in any of the methods described above. For example, where PCR followed by DNA digestion is used, said means preferably include PCR reagents and one or more of the *BsmI*, *ApaI*, or *TaqI* restriction enzymes. Where the method employs Southern Blotting, heteroduplex visualization, or fluorescent labelling techniques for example, probes which bind to the appropriate regions of the vitamin D receptor gene may be included. Where necessary, such probes may be labelled to allow detection, for example by nick-translation, radio- or fluorescent-labelling, or random primer extension whereby the non-labelled nucleotides serve as a template for the synthesis of labelled molecules. Other methods of labelling probes are well known in the art.

20

25

In a preferred feature of the fourth aspect of the present invention, there is provided use of a kit further comprising means for indicating correlation between the genotype of a subject and risk of heart disease. Said means may be in the form of a chart or

30

30 Study Subjects

The Rotterdam Study is a population-based cohort study of 7983 subjects aged 55 or more years, residing in the Ommoord district of the city of Rotterdam in the Netherlands. The study was designed to document the occurrence of disease in the elderly in relation to several potential determinants.¹⁵ A total of 10,275 persons, of whom 9161 (89 percent) were living independently, were invited to participate in the study in 1991. In the independently living subjects, the overall response rate was 77 percent for home interview and 71 percent for examination in a research centre, including measurement of anthropometric characteristics and blood sampling. The Rotterdam Study was approved by the Medical Ethics Committee of the Erasmus University Medical School and written informed consent was obtained from each subject.

The analysis of the association between VDR genotype, myocardial infarction and arrhythmias was performed in a subgroup of men and women participating in the study. Baseline measurements, collected from 1990-1993, included and electrocardiogram (ECG), history of cardiovascular disease, established cardiovascular risk factors, and use of medication. A digitally stored ECG was available for 5931 independently living subjects from the study, but 1453 of these were excluded on the basis of age (>80 yrs), use of a walking aid, diabetes mellitus or use of diuretic, estrogen, thyroid hormone or cytostatic drug therapy. From the 4478 remaining subjects, we studied a random sample of 2000 men and women aged 55 to 80 years. ECG data or DNA samples were not available for 22 subjects, resulting in a final study group of 1978 subjects.

25 Measurements

Height and weight were measured at the initial examination in a standing position without shoes. Myocardial infarction, including so called silent myocardial infarctions, was confirmed by ECG analysis. For 1725 men and women (87%) data

was available on dietary intakes of calcium (mg/day) during the preceding year. These were assessed by food frequency questionnaire and adjusted for energy intake. Age at menopause and current cigarette smoking were assessed by questionnaire. Cardiac arrhythmias were diagnosed by ECG analysis and included the occurrence of sinus irregularities, atrial flutter, and atrial fibrillation and were recorded, confirmed and classified by a physician. For 976 subjects data on cardiac arrhythmias were available (49%). Of these subjects, data on dietary calcium intake were available for 899 subjects (92%).

10 Determination of VDR Genotypes

Genomic DNA was extracted from peripheral venous blood samples according to standard procedures and the anonymous polymorphisms were detected by PCR as previously described¹⁶. Three anonymous polymorphic restriction enzyme recognition sites at the 3' end of the VDR gene, i.e. for BsmI, ApaI, and TaqI, were assessed in relation to each other by a direct molecular haplotyping PCR procedure which we developed¹⁶. This allows us to determine ophase of the alleles at each of the RFLP loci and as a result three frequent haplotype alleles are discerned, encoded 1 (baT; frequency 48%), 2 (BA^t; frequency 40%), 3 (bAT; frequency 10%) combining to six genotypes encoded 11, 12, 13, 22, 23, and 33. Detailed information on haplotype alleles and genotype frequencies in the Rotterdam Study can be found elsewhere¹⁶. The PCR reaction mixture of 25 microlitres contained 100 ng of genomic DNA, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl₂, 0.2 mM dideoxynucleotidetriphosphates, 150 ng of each primer, and 0.2 unit of Super Taq polymerase (HT Biotechnology, Cambridge, UK). The reactions were performed in a DNA thermocycler (model 480, Perkin Elmer) with a cycling protocol of 94°C, 60°C, and 72°C for 1 min each, for 28 cycles. Ten microlitres of PCR product were simultaneously digested with 5 units BsmI, 5 units ApaI, and 5 units TaqI restriction enzyme and 2 microlitres of a 10x concentrated buffer

5

10

15

20

25

RESULTS

Characteristics of the Study Subjects

Anthropometric, and dietary measurements in the men and women with the six VDR genotypes are shown in Table 1. The allele frequencies (1=48.6%; 2=40.6%; and 3=10.8%) and the distribution of genotypes were similar to that reported in a
5 previous study²². There was no difference with regard to age, dietary calcium intake, smoking habits, body mass index, serum HDL-cholesterol, and serum cholesterol in the six genotype groups.

Association with Myocardial Infarction

10 The distribution of myocardial infarction by VDR genotype in men and women is shown in Table 2. There was modest over-representation of both men and women carrying the VDR haplotype allele 1 as compared with subjects without the allele although this did not reach significance. Logistic regression analysis showed that subjects in the heterozygous group had a 1.2 fold increased risk for myocardial
15 infarction and the subjects in the homozygous group had a 1.5-fold increased risk, as compared with subjects not carrying the VDR allele 1. The gene dose effect was 1.2-fold increased risk per copy of the VDR allele 1. The gene dose effect was larger for women when compared to men (RRs were 1.1 (95% confidence interval 0.9 - 1.4) for men and 1.5 (95% confidence interval 1.1 - 2.2) for women) but the interaction
20 term of sex times genotype in the regression model was not significant (P=0.65). The relative risks for myocardial infarction did not change after adjustment for potential confounding factors such as age, body mass index and smoking in the regression analysis. For VDR haplotype allele 2 and haplotype allele 3 no significant differences were observed (data not shown).

Modification of the Association by Dietary Calcium Intake

When the study subjects were stratified according to quartiles of dietary calcium intake, the differences in distribution of myocardial infarction by VDR genotype were restricted to individuals with the highest intake of calcium (1302 mg/day or more). These differences corresponded with 5.4-fold increased risk for heterozygote carriers and 8.3 -fold increased risk for homozygote carriers of VDR haplotype allele 1. Considering age, genotype and myocardial infarction together in a multivariate regression model, we found a significant modifying effect of dietary calcium intake on the VDR genotype effect on risk for myocardial infarction (P=0.04).

Association with Cardiac Arrhythmias

We subsequently analysed the distribution of cardiac arrhythmias by VDR genotype. We did not observe differences in the distribution of arrhythmias by VDR genotype in the total study group. However, in the group with high calcium intake (1302 mg/day or more) there was significant over-representation of cardiac arrhythmias for subjects carrying the VDR haplotype allele 1 as compared with subjects without the allele 1 (Table 4).

Logistic regression analysis showed that subjects in the heterozygous group had a 1.6 fold increased risk for cardiac arrhythmias and the subjects in the homozygous group had a 3.6-fold increased risk, as compared with subjects not carrying the VDR allele 1. The relative risks for cardiac arrhythmia did not change after adjustment for potential confounding factors such as age, body mass index and smoking in the regression analysis. Also when myocardial infarction was entered into the model the relative risks did not change.

DISCUSSION

Calcium channel blocking agents are indicated for the treatment of a variety of cardiovascular diseases, including cardiac arrhythmias, but have also been found associated with increased cardiovascular morbidity^{21,22}. Therefore, the modification by calcium intake of the VDR genotype dependent effect on myocardial infarction we observe opens the possibility that genotyping at the VDR gene locus might be of value in predicting the response to treatment with some of these drugs. Prospective

WO 00/15840

17

PCT/EP99/07720

clinical trials are needed to investigate the clinical and therapeutic implications of our results.

REFERENCES

1. Marian AJ. Genetic risk factors for myocardial infarction. *Curr Opin Cardiol* 1998;13:171-178.
- 5 2. Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. *New Engl J Med* 1996;334:1090-1096.
3. Iacoviello L, Di Castelnuovo A, de Knijff P, et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. *New Engl. J Med* 10 1998;338:79-85.
4. Kuivenhoven JA, Jukema W, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. *New Engl. J Med* 1998;338:86-93.
5. Lind L, Skarfors E, Berglund L, Lithell H, and Ljunghall. Serum calcium: a new, independent, prospective risk factor for myocardial infarction in middle-aged 15 men followed for 18 years. *J Clin Epidemiol* 1997;50:967-973.
6. Haussler MR, Haussler CA, Jurutka PW, et al. The vitamin D hormone and its nuclear receptor: molecular actions and disease states. *J Endocrinol* 1997;154:S57-S73.
- 20 7. Scragg R, Jackson R, Holdaway IM, Lim T, and Beaglehole R. Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community based study. *Int J Epidemiol* 1990;19:559-563.
8. Brunvand L, Haga P, Tangsrud SE, and Haug E. Congestive heart failure caused by vitamin D deficiency? *Acata Paediatr* 1995;84:106-108.
- 25 9. Vintzileos AM, Campbell WA, Soberman SM, and Nochimson DJ. Fetal atrial flutter and X-linked dominant vitamin D resistant rickets. *Obstet Gynecol.* 1985;65:39S-44S.

10. Kessel L. Sick sinus syndrome cured by ... vitamin D? *Geriatrics* 1990;45:83-85.
11. Cooper GS, Umbach DM. Are vitamin D receptor polymorphisms associated
5 with bone density ? *J Bone Miner Res* 1996;11:1841-9.
12. Carling T, Kindmark A, Helleman P, et al. Vitamin D receptor genotypes in primary hyperparathyroidism. *Nature Med* 1995;1:1309-1311.
13. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, and Bell DA. Association of prostate cancer with vitamin D receptor gene polymorphism. *Canc.*
10 *Res.* 1996;56:4108-4110.
14. Uitterlinden AG, Burger H, Huang Q, et al. Vitamin D receptor genotype is associated with radiographic osteoarthritis at the knee. *J Clin Invest* 1997;100:259-263.
15. Hofman A, Grobbee DE, de Jong, PTVM, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. *Eur J Epidemiol* 1991;7:403-22.
16. Uitterlinden AG, Pols HAP, Burger H, et al. A large scale population based study of the association of vitamin D receptor gene polymorphisms with bone mineral density. *J Bone Miner Res* 1996;11:1242-1248.
- 20 17. O'Connell TD, Weishaar RE, and Simpson RU. Regulation of myosin isozyme expression by vitamin D3 deficiency and 1,25-dihydroxyvitamin D3 in the rat heart. *Endocrinology* 1994;134: 899-905
18. Weishaar RE, Kim SN, Saunders D, and Simpson RU. Involvement of vitamin D3 with cardiovascular function III. Effects on physical and morphological
25 properties. *Am J Physiol* 1990;258 (Endocrinol. Metab. 21):E134-E142.
19. Weishaar RE, and Simpson RU. Involvement of vitamin D3 with cardiovascular function II. Direct and indirect effects. *Am J Physiol* 1987;253 (Endocrinol. Metab. 16):E675-E683.

20. Weishaar RE, and Simpson RU. Vitamin D3 and cardiovascular function in rats. J Clin Invest 1987;79:1706-1712.
21. Psaty BM, Heckbert SR, Koepsell TD, *et al.* The risk of myocardial infraction associated with antihypertensive drug therapies. JAMA 1995; 271:620-625.
22. Michalewicz L, and Messerli FH. Cardiac effects of calcium antagonists in systemic hypertension. Am J Cardiol. 1997; 79:39-46.

CLAIMS

1. A method of determining susceptibility to heart disease in a subject, said
5 method comprising analysing genetic material of a subject to determine which of the
B/b, A/a or T/t alleles of the *BsmI*, *ApaI* or *TaqI* sites of the vitamin D receptor gene
is/are present, wherein the b, a or T allele(s) are associated with risk of heart
disease.
- 10 2. A method of determining susceptibility to heart disease according to claim 1,
said method comprising analysing the genetic material of a subject to determine the
haplotype of the *BsmI*, *ApaI* or *TaqI* alleles of the vitamin D receptor.
- 15 3. A method according to claim 2 wherein the haplotype may be determined by
amplification of a relevant portion of the vitamin D receptor gene, followed by
restriction enzyme digestion.
- 20 4. A method of determining susceptibility to heart disease according to claims 1
to 3, said method comprising determining the copy number of the B/b, A/a or T/t
alleles or haplotype of the vitamin D receptor.
5. A method according to any one of the preceding claims further comprising
determining whether the allele(s) present is/are associated with risk of heart disease.
- 25 6. A method according to claim 5 comprising comparing the allele(s) present in
the genetic material of the subject with those known to be associated allele(s) of
vitamin D receptor genotypes having known degrees of risk of heart disease
- 30 7. A method according to any one of the previous claims wherein said method
further comprises determining aspects of calcium metabolism in a subject.
8. A method according to claim 7, wherein daily calcium intake of a subject is
measured.

9. A method according to any one of the preceding claims, wherein said method is performed *in vitro*.

5 10. A method according to claim 9 wherein said method is performed on blood or tissue samples of a subject.

10 11. A method according to any one of the preceding claims wherein the subject is a mammal.

12. A method according to claim 11 wherein the subject is a human.

13. A method according to claims 11 or 12 wherein the subject is male.

15 14. A method according to any one of the previous claims for determining susceptibility of a subject to atrial or ventricular hypertrophy, aortic calcification, myocardial infarction, or hypertension.

20 15. A method according to any one of the preceding claims further comprising treating the subject to reduce the risk of heart disease.

25 16. A method according to claim 15 wherein suitable treatments may include modifications to lifestyle, regular exercise, changes in diet or pharmaceutical preparations.

30 17. A method of predicting the response of a subject to treatment, said method comprising analysing genetic material of a subject to determine which of the B/b, A/a or T/t allele(s) of the vitamin D receptor gene is/are present, in order to determine the underlying cause of the heart disease.

18. A method according to claim 17 wherein said subject is first diagnosed as being susceptible to heart disease in accordance with any one of claims 1 to 16.

19. A method according to claims 17 or 18 further comprising administering the appropriate treatment.

5 20. Use of a kit to determine susceptibility to heart disease in a subject, said kit comprising (i) one or more nucleic acid primer molecules for amplification of a portion of the vitamin D receptor gene, and (ii) means for determining which allele(s) of said gene is/are present.

10 21. A kit for determining susceptibility to heart disease in a subject, said kit comprising (i) one or more nucleic acid primer molecules for amplification of a portion of the vitamin D receptor gene; (ii) means for determining which allele(s) of said gene is/are present; and (iii) means for indicating correlation between said allele(s) and risk of heart disease.

15 22. A kit according to claim 21, said kit comprising DNA control samples, for comparison with DNA sequences of a subject.

20

25



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12Q 1/68	A1	(11) International Publication Number: WO 00/15840 (43) International Publication Date: 23 March 2000 (23.03.00)
<p>(21) International Application Number: PCT/EP99/07720</p> <p>(22) International Filing Date: 10 September 1999 (10.09.99)</p> <p>(30) Priority Data: 9819764.3 10 September 1998 (10.09.98) GB</p> <p>(71) Applicant (for all designated States except US): ERASMUS UNIVERSITEIT ROTTERDAM [NL/NL]; Burgemeester Oudlaan 50, NL-3062 PA Rotterdam (NL).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): UITTERLINDEN, Andreas, Gerardus [NL/NL]; Limes 67, NL-3176 TE Poortugaal (NL). VAN LEEUWEN, Petrus, Thomas, Maria [NL/NL]; Maluslaan 23, NL-1185 KZ Amstelveen (NL). POLS, Huibert, Adriaan, Pieter [NL/NL]; Campanulahof 21, NL-3355 BH Papendrecht (NL).</p> <p>(74) Agents: SHEARD, Andrew, Gregory et al.; Kilburn & Strode, 20 Red Lion Street, London WC1R 4PJ (GB).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: METHOD FOR DETERMINING SUSCEPTIBILITY TO HEART DISEASE BY SCREENING POLYMORPHISMS IN THE -- VITAMIN D RECEPTOR GENE</p>		
<p>(57) Abstract</p> <p>The present invention relates to prognostic method and means for determining susceptibility to heart disease in a subject by screening for polymorphisms in the Vitamin D receptor gene. In particular, the present invention provides a method for determining susceptibility to heart disease, the method comprising analysing the genetic material of a subject to determine which of the B/b, A/a or T/t alleles of the restriction enzyme sites <i>BsmI</i>, <i>Apal</i> and <i>TaqI</i> respectively are present. Specific combinations of alleles represent a haplotype which is associated with susceptibility to heart disease.</p>		

TABLE 1.
Characteristics of the Population According to VDR Genotype

CHARACTERISTIC†	VDR GENOTYPE				P-VALUE
	11	12	13	22	33
Number (%)	493 (24.9)	735 (37.2)	202 (10.2)	351 (17.7)	27 (1.4)
Age (years)	67.0 ± 6.8	67.1 ± 6.8	67.2 ± 7.1	67.0 ± 7.1	67.0 ± 7.1
Body Mass Index (kg/m ²)	26.1 ± 3.7	26.0 ± 3.3	25.8 ± 3.6	26.1 ± 3.4	25.5 ± 2.9
Dietary calcium-intake (mg/day)	1116 ± 350	1122 ± 364	1122 ± 356	1092 ± 369	1158 ± 254
Serum HDL-cholesterol (mmol/l)	1.34 ± 0.37	1.35 ± 0.36	1.36 ± 0.34	1.35 ± 0.37	1.36 ± 0.38
Serum cholesterol (mmol/l)	6.68 ± 1.21	6.63 ± 1.26	6.64 ± 1.16	6.60 ± 1.19	6.60 ± 0.96
Current Smokers (%)	130 (26.4)	172 (23.4)	45 (22.3)	78 (22.2)	6 (22.2)
					0.83‡

† Values are means ± standard deviation; BMI is weight divided by the square height

§ P-value for ANOVA

‡ P-value for Chi-2 test

TABLE 2.

Myocardial Infarction According to *VDR allele 1* Genotype

	Men		Women		All	
	MI (%)	Total	MI (%)	Total	MI (%)	Total
Total	151 (15.8)	954	62 (6.1)	1024	213 (10.8)	1978
by <i>VDR allele 1</i> genotype						
Reference†	39 (14.7)	266	10 (3.5)	282	49 (8.9)	548
Heterozygotes	69 (15.4)	449	31 (6.4)	488	100 (10.7)	937
Homozygotes	43 (18.0)	239	21 (8.3)	254	64 (13.0)	493
χ^2	1.18		5.38		4.43	
P-VALUE	0.55		0.07		0.11	
Odds Ratios for Myocardial Infarct by <i>VDR allele 1</i> genotype [95% CI]						
Crude						
Reference	1.00		1.00		1.00	
Heterozygotes	1.07 [0.72 - 1.71]		1.86 [0.90 - 3.85]		1.23 [0.86 - 1.76]	
Homozygotes	1.28 [0.80 - 2.05]		2.48 [1.15 - 5.39]		1.53 [1.03 - 2.27]	
per copy <i>VDR 1</i> allele	1.13 [0.89 - 1.44]		1.53 [1.07 - 2.20]		1.24 [1.02 - 1.51]	
Age-, BMI-adjusted						
Reference	1.00		1.00		1.00	
Heterozygotes	1.11 [0.72 - 1.71]		1.77 [0.85 - 3.68]		1.22 [0.85 - 1.75]	
Homozygotes	1.33 [0.82 - 2.14]		2.45 [1.12 - 5.34]		1.55 [1.04 - 2.30]	
per copy <i>VDR 1</i> allele	1.15 [0.91 - 1.47]		1.53 [1.06 - 2.22]		1.25 [1.02 - 1.52]	

† "Reference" includes *VDR* genotypes 22, 23, 33; "Heterozygotes" includes 12, 13;
"Homozygotes" includes 11

TABLE 3.
Myocardial Infarction According to VDR allele 1 Genotype by Quartiles of Dietary Calcium Intake

	< 877 mg/day		> 877, < 1076		> 1076, < 1302		≥ 1302	
	MI (%)	Total	MI (%)	Total	MI (%)	Total	MI (%)	Total
Total	43 (10.0)	432	50 (11.6)	431	45 (10.4)	432	49 (11.4)	430
by VDR allele 1 genotype								
Reference†	13 (9.9)	131	14 (12.5)	112	12 (9.6)	125	3 (2.6)	114
Heterozygotes	21 (10.5)	200	24 (11.8)	204	21 (10.0)	210	26 (12.6)	207
Homozygotes	9 (8.9)	101	12 (10.4)	115	12 (12.4)	97	20 (18.3)	109
χ^2	0.19		0.25		0.53		14.17	
P-VALUE	0.91		0.88		0.77		0.0008	
Odds Ratios for Myocardial Infarct by VDR allele 1 genotype [95% CI]								
Crude	1.00		1.00		1.00		1.00	
Reference								
Heterozygotes	1.09 [0.52 - 2.27]		0.93 [0.46 - 1.89]		1.04 [0.49 - 2.20]		5.40 [1.59 - 18.3]	
Homozygotes	0.90 [0.37 - 2.20]		0.82 [0.36 - 1.87]		1.32 [0.56 - 3.09]		8.31 [2.39 - 29.0]	

† "Reference" includes VDR genotypes 22, 23, 33; "Heterozygotes" includes 12, 13; "Homozygotes" includes 11

TABLE 4.
Myocardial Arrhythmias According to VDR allele 1 Genotype by Quartiles of Dietary Calcium Intake

	< 877 mg/day		> 877, < 1076		> 1076, < 1302		≥ 1302	
	MA (%)	Total	MA (%)	Total	MA (%)	Total	MA (%)	Total
Total	37 (12.1)	307	27 (9.2)	292	17 (5.6)	302	31 (10.1)	306
by VDR allele 1 genotype								
Reference†	16 (17.0)	94	6 (8.8)	68	7 (7.7)	91	5 (5.7)	88
Heterozygotes	14 (10.1)	138	14 (10.1)	138	6 (4.4)	135	12 (8.5)	141
Homozygotes	7 (9.3)	75	7 (8.1)	86	4 (5.3)	76	14 (18.2)	77
χ^2	3.19		0.27		1.11		7.80	
P-VALUE	0.20		0.87		0.58		0.02	
Odds Ratios for Myocardial arrhythmias by VDR allele 1 genotype [95% CI]								
Crude								
Reference	1.00		1.00		1.00		1.00	
Heterozygotes	0.57 [0.26 - 1.23]		1.13 [0.41 - 3.12]		0.54 [0.18 - 1.69]		1.60 [0.54 - 4.74]	
Homozygotes	0.51 [0.20 - 1.32]		0.92 [0.29 - 2.92]		0.69 [0.19 - 2.46]		3.63 [1.22 - 10.9]	

† "Reference" includes VDR genotypes 22, 23, 33; "Heterozygotes" includes 12, 13; "Homozygotes" includes 11




FIG. 1

Attorney Docket No. KILS117129

COMBINED DECLARATION AND POWER OF ATTORNEY
IN PATENT APPLICATION

As a below-named inventor, I hereby declare that:

my residence, post office address, and citizenship are as stated below next to my name;

I believe that I am an original, first, and joint inventor of the subject matter that is claimed and for which patent is sought on the invention entitled METHOD FOR DETERMINING SUSCEPTIBILITY TO HEART DISEASE BY SCREENING POLYMORPHISMS IN THE VITAMIN D RECEPTOR GENE, the specification of which was mailed to the Patent and Trademark Office on March 9, 2001, and assigned United States Patent Application No. 09/786,992.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(c), of any foreign application(s) for patent listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s):

Number	Country	Day/Month/Year Filed	Priority Claimed Yes/No
9819764.3	Great Britain	10 September 1998	yes

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(d), of any inventor's certificate listed below. I declare that, upon investigation, I am satisfied that to the best of my knowledge, when filing the application for the inventor's certificate I had the option to file an application for either a patent or an inventor's certificate as to the subject matter of the identified claim or claims forming the basis for the claim of priority:

I hereby claim the benefit under Title 35, United States Code, Section 119(e), of any United States provisional application(s) listed below: NONE

I hereby claim the benefit under Title 35, United States Code, Section 120, of any United States application(s) or PCT international application(s) designating the United States listed below, and, insofar as the subject matter of each of the claims of this application is not

disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a), which occurred between the filing date of the prior application and the national or PCT international filing date of this application: NONE.

Prior PCT Application:

Application No.	Filing Date	Status
PCT/EP99/07720	10 September 1999	abandoned

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith: Bruce E. O'Connor, Reg. No. 24,849; Lee E. Johnson, Reg. No. 22,946; Gary S. Kindness, Reg. No. 22,178; James W. Anable, Reg. No. 26,827; James R. Uhler, Reg. No. 25,096; Jerald E. Nagae, Reg. No. 29,418; Dennis K. Shelton, Reg. No. 26,997; Jeffrey M. Sakoi, Reg. No. 32,059; Ward Brown, Reg. No. 28,400; Robert J. Carlson, Reg. No. 35,472; Marcia S. Kelbon, Reg. No. 34,358; Rodney C. Tullett, Reg. No. 34,034; Daiva K. Tautvydas, Reg. No. 36,077; Mary L. Culic, Reg. No. 40,574; Julie C. VanDerZanden, Reg. No. 38,105; George E. Renzoni, Ph.D., Reg. No. 37,919; and Philip P. Mann, Reg. No. 30,960; and the firm of Christensen O'Connor Johnson Kindness^{PLLC}. Address all telephone calls to Barry F. McGurl at telephone No. 206.695.1775.


Address all correspondence to:

Customer No. 26389


CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue, Suite 2800
Seattle, WA 98101


I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

102

Full Name of Inventor	Citizenship
<u>Andreas Gerardus Uitterlinden</u>	<u>Netherlands</u>
Residence	
<u>Limes 67, NL-3176 TE Poortugaal, Netherlands</u>	
Post Office Address	
<u>Same as above.</u>	
Inventor's Signature	Date
	<u>April 17th 2001</u>

2.52

Full Name of Inventor	Citizenship
<u>Johannes Petrus Thomas Maria Van Leeuwen</u>	<u>Netherlands</u>
Residence	
<u>85 Keizer Karelweg 515, 1185 HP Amstelveen, Netherlands</u>	
Post Office Address	
<u>Same as above.</u>	
Inventor's Signature	Date
	<u>April 18th 2001</u>

Full Name of Inventor	Citizenship
<u>Huibert Adriaan Pieter Pols</u>	<u>Netherlands</u>
Residence	
<u>Campanulahof 21, NL-3355 BH Papendrecht, Netherlands</u>	
Post Office Address	
<u>Same as above.</u>	
Inventor's Signature	Date
	<u>18 Apr / 2001</u>

BFM:jlj